Céline Parmentier
Céline Parmentier has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lysiane Richert
KaLy-Cell, 67115, Plobsheim, France
5 shared publications - Audrey Baze
KaLy-Cell, 67115 Plobsheim, France
4 shared publications - Germaine L. Truisi
Non-Clinical Safety, Merck Serono Research, Merck KGaA, Darmstadt, Germany; Institut für Angewandte Biowissenschaften, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
2 shared publications - Philip Hewitt
Chemical and Preclinical Safety, Merck KGaA , 64293 Darmstadt
2 shared publications - Achilleas Fardellas
Center for Infectious Medicine (CIM), Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
1 shared publication - Alanah Pieters
Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 435, 115831
Evaluation of human relevance of Nicofluprole-induced rat thyroid disruption
- 1 January 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 435, 115831
Open AccessEvaluation of human relevance of Nicofluprole-induced rat thyroid disruption
- Open Access
- 12 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 11005
Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals
Drug-induced liver injury, including cholestasis, is an important clinical issue and economic burden for pharmaceutical industry and healthcare systems. However, human-relevant in vitro information on the ability of other types of chemicals to induce cholestatic hepatotoxicity is lacking. This work aimed at investigating the cholestatic potential of non-pharmaceutical chemicals using primary human hepatocytes cultured in 3D spheroids. Spheroid cultures were repeatedly (co-) exposed to drugs (cyclosporine-A, bosentan, macitentan) or non-pharmaceutical chemicals (paraquat, tartrazine, triclosan) and a concentrated mixture of bile acids for 4 weeks. Cell viability (adenosine triphosphate content) was checked every week and used to calculate the cholestatic index, an indicator of cholestatic liability. Microarray analysis was performed at specific time-points to verify the deregulation of genes related to cholestasis, steatosis and fibrosis. Despite the evident inter-donor variability, shorter exposures to cyclosporine-A consistently produced cholestatic index values below 0.80 with transcriptomic data partially supporting its cholestatic burden. Bosentan confirmed to be hepatotoxic, while macitentan was not toxic in the tested concentrations. Prolonged exposure to paraquat suggested fibrotic potential, while triclosan markedly deregulated genes involved in different types of hepatotoxicity. These results support the applicability of primary human hepatocyte spheroids to study hepatotoxicity of non-pharmaceutical chemicals in vitro.
- 12 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 11005
Open AccessPrimary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals
Drug-induced liver injury, including cholestasis, is an important clinical issue and economic burden for pharmaceutical industry and healthcare systems. However, human-relevant in vitro information on the ability of other types of chemicals to induce cholestatic hepatotoxicity is lacking. This work aimed at investigating the cholestatic potential of non-pharmaceutical chemicals using primary human hepatocytes cultured in 3D spheroids. Spheroid cultures were repeatedly (co-) exposed to drugs (cyclosporine-A, bosentan, macitentan) or non-pharmaceutical chemicals (paraquat, tartrazine, triclosan) and a concentrated mixture of bile acids for 4 weeks. Cell viability (adenosine triphosphate content) was checked every week and used to calculate the cholestatic index, an indicator of cholestatic liability. Microarray analysis was performed at specific time-points to verify the deregulation of genes related to cholestasis, steatosis and fibrosis. Despite the evident inter-donor variability, shorter exposures to cyclosporine-A consistently produced cholestatic index values below 0.80 with transcriptomic data partially supporting its cholestatic burden. Bosentan confirmed to be hepatotoxic, while macitentan was not toxic in the tested concentrations. Prolonged exposure to paraquat suggested fibrotic potential, while triclosan markedly deregulated genes involved in different types of hepatotoxicity. These results support the applicability of primary human hepatocyte spheroids to study hepatotoxicity of non-pharmaceutical chemicals in vitro.
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104736
Weight of Evidence and Human Relevance Evaluation of the Benfluralin Mode of Action in Rats (Part II): Thyroid carcinogenesis
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104736
Weight of Evidence and Human Relevance Evaluation of the Benfluralin Mode of Action in Rats (Part II): Thyroid carcinogenesis
- Open Access
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Non-alcoholic fatty liver disease affects approximately one billion adults worldwide. Non-alcoholic steatohepatitis (NASH) is a progressive disease and underlies the advancement to liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which there are no FDA-approved drug therapies. We developed a hetero-cellular spheroid system comprised of primary human hepatocytes (PHH) co-cultured with crude fractions of primary human liver non-parenchymal cells (NPC) from several matched or non-matched donors, to identify phenotypes with utility in investigating NASH pathogenesis and drug screening. Co-culture spheroids displayed stable expression of hepatocyte markers (albumin, CYP3A4) with the integration of stellate (vimentin, PDGFRβ), endothelial (vWF, PECAM1), and CD68-positive cells. Several co-culture spheroids developed a fibrotic phenotype either spontaneously, primarily observed in PNPLA3 mutant donors, or after challenge with free fatty acids (FFA), as determined by COL1A1 and αSMA expression. This phenotype, as well as TGFβ1 expression, was attenuated with an ALK5 inhibitor. Furthermore, CYP2E1, which has a strong pro-oxidant effect, was induced by NPCs and FFA. This system was used to evaluate the effects of anti-NASH drug candidates, which inhibited fibrillary deposition following 7 days of exposure. In conclusion, we suggest that this system is suitable for the evaluation of NASH pathogenesis and screening of anti-NASH drug candidates.
Open AccessHuman Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Non-alcoholic fatty liver disease affects approximately one billion adults worldwide. Non-alcoholic steatohepatitis (NASH) is a progressive disease and underlies the advancement to liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which there are no FDA-approved drug therapies. We developed a hetero-cellular spheroid system comprised of primary human hepatocytes (PHH) co-cultured with crude fractions of primary human liver non-parenchymal cells (NPC) from several matched or non-matched donors, to identify phenotypes with utility in investigating NASH pathogenesis and drug screening. Co-culture spheroids displayed stable expression of hepatocyte markers (albumin, CYP3A4) with the integration of stellate (vimentin, PDGFRβ), endothelial (vWF, PECAM1), and CD68-positive cells. Several co-culture spheroids developed a fibrotic phenotype either spontaneously, primarily observed in PNPLA3 mutant donors, or after challenge with free fatty acids (FFA), as determined by COL1A1 and αSMA expression. This phenotype, as well as TGFβ1 expression, was attenuated with an ALK5 inhibitor. Furthermore, CYP2E1, which has a strong pro-oxidant effect, was induced by NPCs and FFA. This system was used to evaluate the effects of anti-NASH drug candidates, which inhibited fibrillary deposition following 7 days of exposure. In conclusion, we suggest that this system is suitable for the evaluation of NASH pathogenesis and screening of anti-NASH drug candidates.
- 1 September 2016
- Published by Elsevier in Toxicology Letters
- Vol. 258, 207-215
Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats
- 1 September 2016
- Published by Elsevier in Toxicology Letters
- Vol. 258, 207-215
Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats
- 1 March 2015
- Published by Elsevier in Toxicology Letters
- Vol. 233 (2) , 172-186
Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems
- 1 March 2015
- Published by Elsevier in Toxicology Letters
- Vol. 233 (2) , 172-186
Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S155
Multiple endpoint approach improves prediction of hepatotoxicity
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S155
Multiple endpoint approach improves prediction of hepatotoxicity